Loading...
Loading...
Teva Pharmaceutical Industries Ltd.
TEVA today announced
that it has signed a definitive agreement with Allergan plc
AGN
to acquire Allergan Generics in a transaction valued at $40.5 billion.
Upon closing, Allergan will receive $33.75 billion in cash and shares of
Teva valued today at $6.75 billion, representing an estimated under 10%
ownership stake in Teva, with the number of Teva shares determined based
on Teva's volume weighted average trading prices during the 15 days
prior to the announcement and five days following the announcement. Teva
believes the acquisition will be significantly accretive to non-GAAP
EPS, including expected double-digit non-GAAP EPS accretion in 2016 and
more than 20% accretion in year two and year three following the close
of the
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in